Ines L Paraiso1,2, Johana S Revel1,2,3, Jaewoo Choi1, Cristobal L Miranda1,2, Parnian Lak1,2,3, Chrissa Kioussi2, Gerd Bobe1,4, Adrian F Gombart1,5, Jacob Raber2,6, Claudia S Maier3, Jan F Stevens1,2. 1. Linus Pauling Institute, Oregon State University, Corvallis, OR, 97331, USA. 2. Department of Pharmaceutical Sciences, Oregon State University, Corvallis, OR, 97331, USA. 3. Department of Chemistry, Oregon State University, Corvallis, OR, 97331, USA. 4. Department of Animal & Rangeland Sciences, Oregon State University, Corvallis, OR, 97331, USA. 5. Department of Biochemistry & Biophysics, Oregon State University, Corvallis, OR, 97331, USA. 6. Department of Behavioral Neuroscience, Neurology, and Radiation Medicine, Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Portland, OR, 97239, USA.
Abstract
SCOPE: Sphingolipids including ceramides are implicated in the pathogenesis of obesity and insulin resistance. Correspondingly, inhibition of pro-inflammatory and neurotoxic ceramide accumulation prevents obesity-mediated insulin resistance and cognitive impairment. Increasing evidence suggests the farnesoid X receptor (FXR) is involved in ceramide metabolism, as bile acid-FXR crosstalk controls ceramide levels along the gut-liver axis. The authors previously reported that FXR agonist xanthohumol (XN), the principal prenylated flavonoid in hops (Humulus lupulus), and its hydrogenated derivatives, α,β-dihydroxanthohumol (DXN), and tetrahydroxanthohumol (TXN), ameliorated obesity-mediated insulin resistance, and cognitive impairment in mice fed a high-fat diet. METHODS AND RESULTS: To better understand how the flavonoids improve both, lipid and bile acid profiles in the liver are analyzed, sphingolipid relative abundance in the hippocampus is measured, and linked them to metabolic and neurocognitive performance. XN, DXN, and TXN (30 mg kg-1 BW per day) decrease ceramide content in liver and hippocampus; the latter is linked to improvements in spatial learning and memory. In addition, XN, DXN, and TXN decrease hepatic cholesterol content by enhancing de novo synthesis of bile acids. CONCLUSION: These observations suggest that XN, DXN, and TXN may alleviate obesity-induced metabolic and neurocognitive impairments by targeting the liver-brain axis.
SCOPE: Sphingolipids including ceramides are implicated in the pathogenesis of obesity and insulin resistance. Correspondingly, inhibition of pro-inflammatory and neurotoxic ceramide accumulation prevents obesity-mediated insulin resistance and cognitive impairment. Increasing evidence suggests the farnesoid X receptor (FXR) is involved in ceramide metabolism, as bile acid-FXR crosstalk controls ceramide levels along the gut-liver axis. The authors previously reported that FXR agonist xanthohumol (XN), the principal prenylated flavonoid in hops (Humulus lupulus), and its hydrogenated derivatives, α,β-dihydroxanthohumol (DXN), and tetrahydroxanthohumol (TXN), ameliorated obesity-mediated insulin resistance, and cognitive impairment in mice fed a high-fat diet. METHODS AND RESULTS: To better understand how the flavonoids improve both, lipid and bile acid profiles in the liver are analyzed, sphingolipid relative abundance in the hippocampus is measured, and linked them to metabolic and neurocognitive performance. XN, DXN, and TXN (30 mg kg-1 BW per day) decrease ceramide content in liver and hippocampus; the latter is linked to improvements in spatial learning and memory. In addition, XN, DXN, and TXN decrease hepatic cholesterol content by enhancing de novo synthesis of bile acids. CONCLUSION: These observations suggest that XN, DXN, and TXN may alleviate obesity-induced metabolic and neurocognitive impairments by targeting the liver-brain axis.
Authors: William L Holland; Russell A Miller; Zhao V Wang; Kai Sun; Brian M Barth; Hai H Bui; Kathryn E Davis; Benjamin T Bikman; Nils Halberg; Joseph M Rutkowski; Mark R Wade; Vincent M Tenorio; Ming-Shang Kuo; Joseph T Brozinick; Bei B Zhang; Morris J Birnbaum; Scott A Summers; Philipp E Scherer Journal: Nat Med Date: 2010-12-26 Impact factor: 53.440
Authors: Juergen Graessler; Dominik Schwudke; Peter E H Schwarz; Ronny Herzog; Andrej Shevchenko; Stefan R Bornstein Journal: PLoS One Date: 2009-07-15 Impact factor: 3.240
Authors: Ines L Paraiso; Luce M Mattio; Armando Alcázar Magaña; Jaewoo Choi; Layhna S Plagmann; Margaret A Redick; Cristobal L Miranda; Claudia S Maier; Sabrina Dallavalle; Chrissa Kioussi; Paul R Blakemore; Jan F Stevens Journal: ACS Pharmacol Transl Sci Date: 2021-11-04
Authors: Andreas Giannisis; Kalicharan Patra; Anna K Edlund; Lur Agirrezabala Nieto; Joan Benedicto-Gras; Simon Moussaud; Andrés de la Rosa; Daniel Twohig; Tore Bengtsson; Yuan Fu; Guojun Bu; Greg Bial; Lander Foquet; Christina Hammarstedt; Stephen Strom; Kristina Kannisto; Jacob Raber; Ewa Ellis; Henrietta M Nielsen Journal: Mol Psychiatry Date: 2022-04-13 Impact factor: 13.437